MARKET

IOVA

IOVA

Iovance
NASDAQ

Real-time Quotes | Nasdaq Last Sale

24.96
-0.64
-2.50%
Closed 16:41 09/24 EDT
OPEN
25.31
PREV CLOSE
25.60
HIGH
25.66
LOW
24.44
VOLUME
1.42M
TURNOVER
--
52 WEEK HIGH
54.21
52 WEEK LOW
15.88
MARKET CAP
3.87B
P/E (TTM)
-12.8959
1D
5D
1M
3M
1Y
5Y
BRIEF-Iovance Initiates Clinical Supply Of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy
reuters.com · 3d ago
Iovance Biotherapeutics Launches Clinical Supply of Tumor-Infiltrating Lymphocyte Cell Therapy
MT Newswires · 4d ago
HOOKIPA (HOOK), Merck Collaborate to Treat Head & Neck Cancers
Zacks.com · 09/16 15:24
Cathie Wood's ARK Invest Posts Fund Sales For Friday, Sept. 10, 2021: IOVA, NSTG, U, NVDA, TRMB, IRDM, TTD, LC, CLLS, CRBU, DRNA, PSTG, PSTI, NVS, SPR
Iovance Biotherapeutics (IOVA) - 132,377  Nanostring Technologies (NSTG) - 55,617  Unity Software (U) - 138,794  Nvidia (NVDA) - 300 Trimble (TRMB) - 15,880  Iridium
Benzinga · 09/13 14:52
Artisan Partners Remains ‘Patient’ in Iovance Biotherapeutics (IOVA)
Artisan Partners, a high value-added investment management firm, published its ‘Artisan Small Cap Fund’ second quarter 2021 investor letter – a copy of which can be downloaded here. A return of 4.36% was recorded by its Investor Class: ARTSX, 4.40% by its ...
Insider Monkey · 09/06 17:11
Cathie Wood's ARK Invest Posts Fund Sales For Monday, Aug. 30, 2021: IOVA, MCRB, ISRG, BABA, NXPI, GOOG, MELI, SE, PSTI, CLLS
Iovance Biotherapeutics (IOVA) - 71,749 Seres Therapeutics (MCRB) - 846,468 Intuitive Surgical (ISRG) - 1,700 Alibaba Group Golding (BABA) - 15,089 NXP Semiconductors (NXPI)
Benzinga · 08/31 14:57
Cathie Wood's ARK Invest Posts Fund Sales For Friday, Aug. 27, 2021: MCRB, NSTG, IOVA, BABA, LC, OKTA, CLLS, PSTI, BMY
Seres Therapeutics (MCRB) - 1,282,095  NanoString Technologies (NSTG) - 66,400  Iovance Biotherapeutics (IOVA) - 444,050  Alibaba Group (BABA) - 13,593  LendingClub (LC)
Benzinga · 08/30 14:39
Cathie Wood's ARK Invest Posts Fund Sales For Thursday, Aug. 26, 2021: NTDOY, IOVA, NSTG, SE, XONE, BABA, LC, SQ, OKTA, MCRB, PSTI, SEER, RHHBY, BMY, GOOG, TRMB
Nintendo (NTDOY) - 38,500 Shares Iovance Biotherapeutics (IOVA) - 302,190 NanoString Technologies (NSTG) - 144,340 Sea (SE) - 71,593 ExOne (XONE) - 10,000 Alibaba (BABA) - 46,900 LendingClub (LC) - 32,700 Square
Benzinga · 08/27 13:16
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IOVA. Analyze the recent business situations of Iovance through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IOVA stock price target is 40.31 with a high estimate of 86.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 333
Institutional Holdings: 178.17M
% Owned: 114.92%
Shares Outstanding: 155.03M
TypeInstitutionsShares
Increased
101
22.19M
New
45
8.51M
Decreased
52
18.11M
Sold Out
62
7.48M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Director
Iain Dukes
President/Chief Executive Officer/General Counsel/Secretary
Frederick Vogt
Chief Financial Officer/Chief Accounting Officer
Jean-marc Bellemin
Chief Operating Officer
Igor Bilinsky
Vice President - Finance
Michael Swartzburg
Other
Friedrich Graf Finckenstein
Director
Athena Countouriotis
Independent Director
Ryan Maynard
Independent Director
Merrill McPeak
Independent Director
Wayne Rothbaum
Independent Director
Michael Weiser
No Data
About IOVA
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company has developed a shorter manufacturing process for Tumor infiltrating lymphocyte (TIL) therapy known as Generation 2 (Gen 2), which yields a cryopreserved TIL product. Its lead product candidates include lifileucel for metastatic melanoma and LN-145 for metastatic cervical cancer. In addition to metastatic melanoma and metastatic cervical cancer, it is investigating TIL therapy and peripheral blood lymphocyte therapy for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer and chronic lymphocytic leukemia.

Webull offers kinds of Iovance Biotherapeutics Inc stock information, including NASDAQ:IOVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IOVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IOVA stock methods without spending real money on the virtual paper trading platform.